Collegium is a diversified biopharmaceutical company that commercializes prescription medications in pain management and attention-deficit/hyperactivity disorder (ADHD) in the United States. The company's pain portfolio includes abuse-deterrent and conventional opioid formulations, buprenorphine for chronic pain, and medications for opioid-induced constipation, while its ADHD portfolio features an evening-dosed stimulant medication designed to improve medication adherence. Collegium generates revenue by selling these products through two dedicated sales forces to healthcare providers, wholesalers, pharmacies, and managed care organizations, leveraging proprietary formulation technologies and intellectual property protections across its branded product lines.